NWS
62
-2
K
53
2
SYK
64
-4
ED
48
3
MRO
55
3
JNPR
46
3
STI
47
-12
DVA
72
2
EW
37
-2
UHS
54
3
COST
58
-2
WAT
47
5
HON
65
-2
NWL
44
-4
EQIX
60
-2
DVN
16
3
NTAP
64
2
DAL
80
-4
DTE
50
3
M
20
-4
NWS
62
-2
K
53
2
SYK
64
-4
ED
48
3
MRO
55
3
JNPR
46
3
STI
47
-12
DVA
72
2
EW
37
-2
UHS
54
3
COST
58
-2
WAT
47
5
HON
65
-2
NWL
44
-4
EQIX
60
-2
DVN
16
3
NTAP
64
2
DAL
80
-4
DTE
50
3
M
20
-4
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
61

AKRO
Akero Therapeutics

Last Price:
31.22
Seasonality Move:
5.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Akero Therapeutics Price Quote

$31.22
+0.58 (+1.91%)
(Updated: November 21, 2024 at 4:25 PM ET)

Akero Therapeutics Key Stats

Buy
61
Akero Therapeutics (AKRO) is a Buy
Day range:
$29.88 - $31.60
52-week range:
$15.32 - $37.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.79%
Volume:
443.2K
Avg. volume:
608.9K
1-year change:
83.77%
Market cap:
$2.1B
Revenue:
$0
EPS:
$-3.78

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$211.6M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $370.4M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$112.2M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

  • Who Are Akero Therapeutics's Competitors?
    Below is a list of companies who compete with Akero Therapeutics or are related in some way:
    • 89bio Inc (ETNB)
    • iBio Inc (IBIO)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Akero Therapeutics Dividend Yield

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -12.36%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 48.27
Upside from Last Price: 57.57%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    114.4M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1.3M AKRO shares are owned by insiders